"Reference to IGF-1 and VEGF as Surrogate Markers in a Study into Prevention of Breast Carcinoma, Using Toremifene on Women of Defined High-Risk Groups."

According to an abstract submitted by the authors to the 1st Milan Breast Cancer Conference, held June 17-19, 1999 in Milan, Italy, "Introduction: The concept for prevention of breast carcinoma has been checked in international studies in recent years. Some of the findings have proved to be highly variable and are discussed and interpreted. A pilot phase of a study into prevention of breast carcinoma was initiated at Gynecological Hospital of Charite [Berlin, Germany] in 1997. Toremifen, an antiestrogen of the second generation, is being applied to 200 women of defined high-risk groups. The pilot phase was conceptualized for the purpose of checking on feasibility and...

Want to see the full article?

• Purchase this article for only $3.00